Quest Diagnostics opened higher at $255.14, compared with its previous close of $252.92. In the last trading session, the stock traded between $250.95 and $256.99. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Quest Diagnostics is now worth
$ 171.81
giving a profit of
$ 71.81 (71.81%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-0.74 (-0.29%)
Day High
$256.99
Day Low
$250.95
Day Open
$255.14
Prev Close
$252.92
Volume
2,56,822
1W Return
3.51%
1M Return
8.72%
3M Return
7.23%
6M Return
33.20%
1Y Return
44.28%
Market Cap ($ Mn)
27,745
PE Ratio
25.77
PB Ratio
3.55
PEG Ratio
26.00
ROE
14.79%
ROCE
11.25%
EPS (TTM)
$2.82
1 Week
3.51%
1 Month
8.72%
3 Months
7.23%
6 Months
33.20%
9 Months
38.30%
Quest Diagnostics Q3FY26 Results: Revenue up 10% YoY, adjusted EPS rises 15%
Revenue rose 10% YoY to $3.1 billion in Q3FY26. Adjusted EPS increased 15.4% to $3.00, beating prior year's $2.60. Full-year revenue guidance raised to $12.065–$12.105 billion. Organic volume growth hit 14.4%, driven by hospital and consumer channels. PAMA regulatory headwinds estimated at ~1% of 2027 revenue.
8 days agoQuest Diagnostics adds two new blood-based Alzheimer's biomarker tests to AD-Detect portfolio
Quest Diagnostics adds FDA-cleared Elecsys pTau217 test to AD-Detect portfolio in Q4. New multi-biomarker panel launches in August with 10% indeterminate rate. Roche test supports rule-in and rule-out assessment across care settings. Combined biomarkers reduce ambiguity vs 15%-20% industry benchmark.
2mo agoQuest Diagnostics raises FY26 guidance after Q2 revenue rises 10.2%
Quest Diagnostics Incorporated reported Q2 net revenue growth of 10.2% to $3.043 billion, with adjusted diluted EPS rising 19.1% to $3.12. Following the favorable resolution of tax contingencies, the company raised its full-year 2026 revenue guidance to $11.95 billion–$12.05 billion and its reported diluted EPS guidance to $9.97–$10.17.
3mo agoBaird raises Quest Diagnostics price target to $236
Baird analyst Eric Coldwell maintained a Neutral rating on Quest Diagnostics and raised the price target to $236 from $232, indicating a slightly improved valuation outlook.
3mo agoQuest integrates oncology tests via OncoEMR pilot
Quest Diagnostics integrates its Haystack MRD and genomic profiling services into Flatiron Health's OncoEMR via a pilot program with American Oncology Network. The initiative aims to simplify complex molecular test ordering for 4,700 clinicians across 1,600 locations, with a full nationwide launch planned for the second half of the year.
3mo agoQuest Diagnostics gains NY approval for Haystack MRD test
Quest Diagnostics secured NYSDOH CLEP approval for its Haystack MRD test, expanding availability to all 50 U.S. states for detecting residual disease in solid tumor cancers.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $709.18 | +0.71% | $2,62,217.18M | 33.49 | |
| $236.98 | +1.24% | $1,66,722.78M | 38.52 | |
| $436.00 | +2.73% | $62,846.78M | - | |
| $181.15 | -0.18% | $51,071.44M | 30.34 | |
| $480.07 | +0.67% | $47,165.92M | 104.98 | |
| $575.98 | +2.32% | $45,376.28M | 39.00 | |
| $275.06 | -1.43% | $45,329.89M | 32.52 | |
| $290.06 | +0.44% | $43,799.06M | 40.22 | |
| $1,718.61 | +1.19% | $34,435.79M | 31.52 | |
| $368.16 | +2.20% | $29,857.78M | 27.72 | |
| $185.31 | +1.49% | $24,867.86M | - | |
| $677.56 | -2.18% | $18,952.71M | 35.27 |
An investment of $100 made 5 years ago in Quest Diagnostics is now worth
$ 171.81
giving a profit of
$ 71.81 (71.81%)
Note: Past profits do not guarantee future returns.
